{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:11:10Z","timestamp":1794971470279,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"M\u00fchlenkreiskliniken"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Following the pivotal phase II trial BOLT, the Hedgehog (Hh) inhibitor sonidegib was approved in the EU to treat locally advanced basal cell carcinoma (laBCC) in patients not amenable to surgery or radiotherapy. We report safety data from the interim analysis of the real-world NISSO study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>NISSO is an ongoing non-interventional, multinational, post-authorization safety study (NCT04066504). Patients with laBCC are treated with sonidegib 200\u00a0mg orally once daily and followed for 3\u00a0years. Dose modifications were allowed according to the local prescribing information.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between May 6, 2019, and March 15, 2022, 321 patients with laBCC were enrolled at 46 European sites (data cut-off: June 22, 2023). Treatment was discontinued in 241 (75.1%) patients, with the main reasons being the patient\/guardian decision (n\u2009=\u200969, 28.6%), treatment success (n\u2009=\u200940, 16.6%) and the physician decision (n\u2009=\u200935, 14.5%). The median duration of sonidegib exposure was 8.8\u00a0months (4.4\u201313.7\u00a0months). Overall, 284 (88.5%) patients had\u2009\u2265\u2009one treatment-emergent adverse event (TEAE). Most TEAEs were\u2009\u2264\u2009grade 2 and the most common were muscle spasms (n\u2009=\u2009141; 43.9%), dysgeusia (n\u2009=\u2009119; 37.1%), and alopecia (n\u2009=\u200997; 30.2%). After 3\u00a0months of treatment, the cumulative rates of muscle spasms, dysgeusia, and alopecia were 21.8%, 16.2%, and 3.7%, respectively. TEAEs led to treatment discontinuation in 59 (18.4%) patients, while 149 (46.4%) patients had at least one TEAE leading to dose reduction or interruption. Serious drug-related TEAEs were reported in 13 (4.1%) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results confirm the safety profile previously observed. Most patients experienced the onset of common TEAEs after 3\u00a0months of treatment, and the cumulative incidence of most common TEAEs was 10\u201320% lower compared to the BOLT study, except for dysgeusia and fatigue that had a similar incidence. The percentage of patients experiencing TEAEs requiring interruption or dose reduction was similar to the BOLT study, while the proportion of patients with TEAE leading to discontinuation of sonidegib was lower. This study demonstrates that the tolerability of sonidegib is manageable in routine clinical practice.<\/jats:p>\n                <jats:p>Trial registration.<\/jats:p>\n                <jats:p>NCT04066504.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-13101-z","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T01:21:48Z","timestamp":1731547308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Ralf","family":"Gutzmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Scalvenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma Mar\u00eda","family":"P\u00e9rez-Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Fern\u00e1ndez-de-Misa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Botella-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"G\u00fcneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Arntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"issue":"21","key":"13101_CR1","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1056\/NEJMra044151","volume":"353","author":"AI Rubin","year":"2005","unstructured":"Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"13101_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jaad.2018.03.060","volume":"80","author":"MC Cameron","year":"2019","unstructured":"Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, et al. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80(2):303\u201317.","journal-title":"J Am Acad Dermatol"},{"key":"13101_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1750-1172-3-32","volume":"3","author":"ML Lo","year":"2008","unstructured":"Lo ML. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32.","journal-title":"Orphanet J Rare Dis"},{"issue":"7418","key":"13101_CR4","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/bmj.327.7418.794","volume":"327","author":"CS Wong","year":"2003","unstructured":"Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327(7418):794\u20138.","journal-title":"BMJ"},{"key":"13101_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113254","volume":"192","author":"K Peris","year":"2023","unstructured":"Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 2023;192: 113254.","journal-title":"Eur J Cancer"},{"issue":"6","key":"13101_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","volume":"16","author":"MR Migden","year":"2015","unstructured":"Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716\u201328.","journal-title":"Lancet Oncol"},{"issue":"1","key":"13101_CR7","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1186\/s12885-021-08968-1","volume":"21","author":"R Gutzmer","year":"2021","unstructured":"Gutzmer R, Robert C, Loquai C, Schadendorf D, Squittieri N, Arntz R, et al. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. BMC Cancer. 2021;21(1):1244.","journal-title":"BMC Cancer"},{"issue":"6","key":"13101_CR8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bjd.18552","volume":"182","author":"R Dummer","year":"2020","unstructured":"Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369\u201378.","journal-title":"Br J Dermatol"},{"issue":"5","key":"13101_CR9","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s13555-021-00588-8","volume":"11","author":"R Gutzmer","year":"2021","unstructured":"Gutzmer R, Loquai C, Robert C, Dr\u00e9no B, Guminski A, Lewis K, et al. Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis. Dermatol Ther (Heidelb). 2021;11(5):1839\u201349.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"13101_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-S\u00e9guin","year":"2017","unstructured":"Basset-S\u00e9guin N, Hauschild A, Kunstfeld R, Grob J, Dr\u00e9no B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334\u201348.","journal-title":"Eur J Cancer"},{"key":"13101_CR11","unstructured":"EMA. Summary of Product Characteristics, Odomzo 200 mg Hard Capsules. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/odomzo-epar-product-information_en.pdf. Accessed April 4, 2024."},{"issue":"7","key":"13101_CR12","doi-asserted-by":"publisher","first-page":"T565","DOI":"10.1016\/j.ad.2023.06.011","volume":"114","author":"OM Moreno-Arrones","year":"2023","unstructured":"Moreno-Arrones OM, B\u00e9a-Ardebol S, Mayo-Martinez F, P\u00e9rez-Pastor G, Torres-Navarro I, Bonfill-Ort\u00ed M, et al. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study. Actas Dermosifiliogr. 2023;114(7):T565\u201371.","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"13101_CR13","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s13555-021-00619-4","volume":"11","author":"K Lewis","year":"2021","unstructured":"Lewis K, Dummer R, Farberg AS, Guminski A, Squittieri N, Migden M. Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial. Dermatol Ther (Heidelb). 2021;11(6):2225\u201334.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"13101_CR14","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/j.jaad.2020.12.006","volume":"84","author":"A Villani","year":"2021","unstructured":"Villani A, Costa C, Fabbrocini G, Ruggiero A, Scalvenzi M. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series. J Am Acad Dermatol. 2021;84(4):e211\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"13101_CR15","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1111\/jdv.17332","volume":"35","author":"R Gutzmer","year":"2021","unstructured":"Gutzmer R, Schulze HJ, Hauschild A, Leiter U, Meier F, Haferkamp S, et al. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS. J Eur Acad Dermatol Venereol. 2021;35(8):1678\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"13101_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104066","volume":"189","author":"P Bossi","year":"2023","unstructured":"Bossi P, Ascierto PA, Basset-Seguin N, Dreno B, Dummer R, Hauschild A, et al. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. Crit Rev Oncol Hematol. 2023;189: 104066.","journal-title":"Crit Rev Oncol Hematol"},{"key":"13101_CR17","doi-asserted-by":"crossref","unstructured":"Heppt MV, Gebhardt C, Hassel JC, Alter M, Gutzmer R, Leiter U, et al. Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives. Cancers (Basel). 2022;14(19).","DOI":"10.3390\/cancers14194547"},{"key":"13101_CR18","doi-asserted-by":"crossref","unstructured":"Herms F, Baroudjian B, Delyon J, Laly P, Tetu P, Lebbe C, et al. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: a Retrospective Study. Acta Derm Venereol. 2022;102:adv00740.","DOI":"10.2340\/actadv.v102.1995"},{"key":"13101_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100844","volume":"35","author":"N Bertrand","year":"2021","unstructured":"Bertrand N, Guerreschi P, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma. EClinicalMedicine. 2021;35: 100844.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"13101_CR20","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1111\/exd.14882","volume":"32","author":"E Dika","year":"2023","unstructured":"Dika E, Melotti B, Comito F, Tassone D, Baraldi C, Campione E, et al. Neoadjuvant treatment of basosquamous carcinomas with Sonidegib: An innovative approach. Exp Dermatol. 2023;32(11):2038\u20139.","journal-title":"Exp Dermatol"},{"issue":"1","key":"13101_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/1346-8138.16970","volume":"51","author":"A Paradisi","year":"2024","unstructured":"Paradisi A, Piccerillo A, Bocchino E, Cappilli S, Ricci C, Di Stefani A, et al. Surgery after sonidegib treatment achieves complete response in locally advanced basal cell carcinoma of the face. J Dermatol. 2024;51(1):106\u20139.","journal-title":"J Dermatol"},{"issue":"6","key":"13101_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac063","volume":"27","author":"A Villani","year":"2022","unstructured":"Villani A, Fabbrocini G, Costa C, Potestio L, Scalvenzi M. Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas. Oncologist. 2022;27(6): e533.","journal-title":"Oncologist"},{"key":"13101_CR23","unstructured":"Nicole Basset-Seguin, Mourad Djermane, Sophie Dalac, Laurent Mortier, Olivier Dereure, Marie Beylot Barry. Reasons of sonidegib discontinuation in patients with locally advanced basal cell carcinoma: a real-world analysis from the French registry caraderm. Presented at EADO 2024 (poster n.228)"},{"issue":"9","key":"13101_CR24","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1111\/jdv.16230","volume":"34","author":"R Dummer","year":"2020","unstructured":"Dummer R, Ascierto PA, Basset-Seguin N, Dr\u00e9no B, Garbe C, Gutzmer R, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020;34(9):1944\u201356.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"35","key":"13101_CR25","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2217\/fon-2022-1290","volume":"19","author":"F Herms","year":"2023","unstructured":"Herms F, Basset-Seguin N. Response to \u201cHedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis.\u201d Future Oncol. 2023;19(35):2335\u20136.","journal-title":"Future Oncol"},{"key":"13101_CR26","doi-asserted-by":"crossref","unstructured":"Grossmann LE, Ramelyte E, N\u00e4geli MC, Dummer R. Eight Years of Real-Life Experience with Smoothened Inhibitors in a Swiss Tertiary Skin Referral Center. Cancers (Basel). 2022;14(10).","DOI":"10.3390\/cancers14102496"},{"key":"13101_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.26502\/acmcr.96550535","volume":"6","author":"C Di Raimondo","year":"2022","unstructured":"Di Raimondo C, Petruzzellis A, Maramao FS, Lombardo P, Lozzi F, Campione E, Bianchi L. Re-Challenge with Sonidegib after Vismodegib Discontinuation in a Near-Centenarian Patient with Locally Advanced Basal Cell Carcinoma. Arch Clin Med Case Rep. 2022;6:636\u20138.","journal-title":"Arch Clin Med Case Rep"},{"issue":"2","key":"13101_CR28","first-page":"150","volume":"158","author":"F Comito","year":"2023","unstructured":"Comito F, Gagliano A, Sperandi F, Dika E, Savoia F, Melotti B. Retreatment with sonidegib in a patient with multiple basal cell carcinomas and multiple comorbidities: a complex real-life scenario. Ital J Dermatol Venerol. 2023;158(2):150\u20132.","journal-title":"Ital J Dermatol Venerol"},{"issue":"5","key":"13101_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15095","volume":"34","author":"A Piccerillo","year":"2021","unstructured":"Piccerillo A, Di Stefani A, Costantini A, Peris K. Sonidegib after vismodegib discontinuation in a patient with Gorlin-Goltz syndrome and multiple basal cell carcinomas. Dermatol Ther. 2021;34(5): e15095.","journal-title":"Dermatol Ther"},{"key":"13101_CR30","doi-asserted-by":"crossref","unstructured":"Puig S, Serra-Guill\u00e9n C, P\u00e9rez-Pastor G, Mart\u00ednez-Domenech \u00c1, Fern\u00e1ndez-de-Misa Cabrera R. Experience with sonidegib in patients with advanced basal cell carcinoma: case reports. Drugs Context. 2022;11.","DOI":"10.7573\/dic.2022-3-8"},{"issue":"5","key":"13101_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.260","volume":"3","author":"F Venturi","year":"2023","unstructured":"Venturi F, Trane L, Silvestri F, Zuccaro B, Magnaterra E, De Giorgi V. Tolerance of sonidegib after intolerance of vismodegib-Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome). Skin Health Dis. 2023;3(5): e260.","journal-title":"Skin Health Dis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13101-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T02:02:17Z","timestamp":1731549737000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13101-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13101"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13101-z","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"16 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by ethics committees of participating study centers: Ethics Committee of the MHH Hannover; Ethics Committee of Westphalia-Lippe; Ethics Committee of the Christian-Albrechts-Universit\u00e4t zu Kiel; Ethics Committee of the Saxony-Anhalt Medical Association; Ethics Committee of the Medical Association of Thuringia; Ethics Committee of the Medical Faculty of the University of Duisburg-Essen; Ethics Committee of the University of T\u00fcbingen; Ethics Committee of the Albert-Ludwigs-University Freiburg; Ethics Committee of the Medical Association of Lower Saxony; Ethics Committee of the University of Regensburg; Ethics Committee of the University of L\u00fcbeck; Ethics Committee of the Rhineland-Palatinate Medical Association; Ethics Committee of the Medical Association of Hesse; Ethics Committee of the North Rhine Medical Association; Ethics Committee of the Medical Faculty of the Ruhr University Bochum; Ethics Committee of the Goethe University Frankfurt; Ethics Committee Hamburg; Ethics Committee of the University of Ulm; Ethics Committee of the Technical University of Munich; Ethics Committee Bad Oeynhausen; Ethics Committee at the Technical University of Dresden; Ethics Committee Berne; Ethics Committee Zurich; Comitato Etico Istituto Nazionale Tumori IRCCS Fondazione \"G. Pascale\"; Comitato Etico I.R.C.C.S. Istituto Tumori \u201cGiovanni Paolo II\u201d; Comitato Etico Interaziendale Novara; Comitato Etico Universit\u00e0 Federico II; Comitato Etico Fondazione Policlinico Universitario Agostino Gemelli IRCCS \u2013 Universit\u00e0 Cattolica del Sacro Cuore; Comitato Etico ASL Avezzano\/Sulmona\/L\u2019Aquila Teramo; Comitato Etico Regionale Liguria; Comitato Etico di Area Vasta Centro; Comitato Etico Fondazione IRCCS \u201cIstituto Nazionale dei Tumori\u201d; Comitato Etico Istituto Dermopatico dell\u2019Immacolata \u2013 IRCCS; Comitato Etico di Brescia; Comitato Etico della Romagna (CEROM); Ethics Committee for Clinical Research of Hospital Cl\u00ednic of Barcelona; Ethics Committee of Hospital of Nuestra Se\u00f1ora de la Candelaria; Ethics Committee of Hospital of Ram\u00f3n y Cajal; Research Ethics Committee \/ Ethics Committee for Drug Research of the Dr. Negr\u00edn University Hospital of Gran Canaria; Ethics Committee of Galicia (SERGAS); Ethics Committee of the Hospital of Vall d'Hebron; Ethics Committee of University Hospital of La Paz; Ethics Committee of Hospital of Santa Creu i Sant Pau; Ethics Committee of Hospital of La Fe; Ethics Committee of University General Hospital of Valencia; Ethics Committee of Hospital of Germans Trias i Pujol; Ethics Committee of University Hospital of V\u00edrgen de la Macarena (site was not initiated).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RG served as consultant for BristolMyers Squibb, MerckSharpDohme, Novartis, GlaxoSmithKline, Amgen, Almirall-Hermal, Pierre-Fabre, SUN Pharma, Immunocore, Delcath, Merck Healthcare, Sanofi\/Regeneron. RG received honoraria for lectures from BristolMyers Squibb, MerckSharpDohme, Novartis, Amgen, Merck Healthcare, Almirall-Hermal, Pierre-Fabre, Sanofi\/Regeneron, SUN Pharma. RG received travel support from Pierre-Fabre, SUN Pharma, Boehringer Ingelheim. RG received research grants from Sanofi\/Regeneron, Merck Healthcare, Amgen, SUN Pharma, KyowaKirin, Almirall-Hermal. UL served as a consultant to MSD, Novartis, Sanofi, Sun Pharma, received travel support from Sun Pharma and Pierre Fabre, speakers\u2019 fees from Sun Pharma, Sanofi, MSD, Novartis and institutional grants from MSD, outside the submitted work. PM received honoraria for lectures and presentations from MSD, Novartis, BMS, Pierre Fabre, Sanofi Genzyme, Immunocore, Delcath, Almirall Hermal, Sun Pharma, Regeneron. PM received travel support from MSD, BMS, Sun Pharma, Novartis and served as consultant for Novartis, BMS, Pierre Fabre, Sanofi Genzyme, Beiersdorf, MSD, Beiersdorf, Biotech, Regeneron, Sun Pharma. KCK serves as consultant to Philogen, BMS, MSD, Sanofi Aventis, Immunocore and received travel grants and speaker fees from Philogen, Pierre Fabre, BMS, MSD, Sun Pharma, Sanofi Aventis, Novartis, Medac and has received research support from Novartis. PAA has\/had a consultant\/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, Sun Pharma, Sanofi, Sandoz, Immunocore, Italfarmaco, Boehringer-Ingelheim, Regeneron, Pfizer, Nouscom, Lunaphore, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer, Erasca, Philogen, Biontech, Anaveon. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi and travel support from Pfizer, Bio-Al Health, Replimmune, MSD, Pierre Fabre, Philogen. MS declares no conflicts of interest. KP reports grants and personal fees from Sanofi, Novartis, Abbvie, Almirall, Philogen, Leo Pharma, Lilly, Janssen, Pierre Fabre, Sun Pharma, Biogen, Galderma. KP received speaker fees from Lilly, Sanofi, Sun Pharma. GMPP has conflicts of interest with Sun Pharma, Almirall and La Roche-Posay. RFdM has\/had a consultant\/advisory role for Takeda, Kyowa Kirin, Recordati, Sun Pharma and received travel support from Kyowa Kirin, Sun Pharma, Janssen, UCB. RBE and REH have no conflicts of interest to state. AH reports grants and personal fees from Agenus, Almirall, Amgen, BMS, CureVac, Dermagnostix, Eisai, Highlight Therapeutics, Huya Biosciences, IO Biotech, Immunocore, Incyte, Iovance, Kyowa Kirin, MerckPfizer, MSD\/Merck, NeraCare, Novartis Pharma, Philogen, Pierre Fabre, Replimune, Regeneron, Roche, Sanofi-Genzyme, Seagen, Xenthera, and from Sun Pharma outside the submitted work. SM, NG, and RA are employees of Sun Pharmaceuticals Industries and SUN Pharmaceuticals Germany GmbH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1401"}}